Drug intelligence / Profile preview

Rebone-T

Development stage: Unknown
Lead developer: Shanghai ReBone Biomedical Technology
Modality: Recombinant Proteins and Enzymes
Administration: Subcutaneous

Overview

Rebone-T (瑞邦骨泰) is a pharmaceutical product developed and marketed in China for the treatment of osteoporosis and related bone disorders. It is a recombinant human parathyroid hormone (rhPTH 1-34), which acts as an anabolic agent to stimulate new bone formation. The drug mimics the activity of endogenous parathyroid hormone, promoting osteoblast activity and increasing bone mineral density. Rebone-T is primarily indicated for postmenopausal women with osteoporosis at high risk of fracture, as well as men with primary or hypogonadal osteoporosis who are at increased risk for fractures.

Brand names: Rebone-T瑞邦骨泰

Targets

PTH1R (Parathyroid hormone/Parathyroid hormone-related peptide receptor type 1)

Beyond the preview

Go deeper on Rebone-T.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Rebone-T.

Explore the full profile